Monitorización continua de glucosa para cribado de alteraciones hidrocarbonadas en fibrosis quística

Martín-Frías, Maria; Ferreiro, Adelaida Lamas; Alcol, E. Colino; Gómez, M. Ángeles Álvarez; Valverde, Rosa Yelmo; Castellanos, Raquel Barrio

doi:10.1016/j.anpedi.2008.10.012

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the index test domain of QUADAS-2, three records were deemed as having a high risk of bias. In these articles, the authors defined cut-off values for the index tests based on the OGTT results [27,32,40]. The reference standard domain was considered at a low risk of bias in all but one case [41].…”

Section: Risk Of Bias and Applicability Assessmentmentioning

confidence: 99%

“…In 9% of the papers, the flow and timing domain was considered to have a high risk of bias. The source of bias in this section was the discrepancy between the target and accrued population size in the articles [30,32,41]. All studies had low or unclear applicability concerns in the "patient selection" and "reference standard" domains.…”

Section: Risk Of Bias and Applicability Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Screening Methods for Diagnosing Cystic Fibrosis-Related Diabetes: A Network Meta-Analysis of Diagnostic Accuracy Studies

et al. 2021

View full text Add to dashboard Cite

Background: Cystic fibrosis-related diabetes (CFRD) has become more common due to higher life expectancy with cystic fibrosis. Early recognition and prompt treatment of CFRD leads to improved outcomes. Methods: We performed a network meta-analysis (NMA) in order to identify the most valuable diagnostic metrics for diagnosing CFRD out of available screening tools (index test), using the oral glucose tolerance test as a reference standard. Pooled sensitivity (Se), specificity (Sp), and superiority indices were calculated and used to rank the index tests. Results: A total of 31 articles with 25 index tests were eligible for inclusion. Two-day, continuous glucose monitoring (CGM) ranked the highest (Se: 86% Sp: 76%), followed by glucose measurement from blood capillary samples (Se: 70%, Sp: 82%) and three-day CGM (Se: 96%, Sp: 56%). When we compared the CGM of different durations, two-day CGM performed best (Se: 88%, Sp: 80%), followed by three-day (Se: 96%, Sp: 59%) and six-day CGM (Se: 66%, Sp: 79%). Conclusions: Considering its overall performance ranking, as well as the high sensitivity, two-day CGM appears to be a promising screening test for CFRD.

show abstract